Cytopia Lodges IND for JAK2 Inhibitor CYT387

MELBOURNE, Australia, June 22 /PRNewswire/ -- Cytopia Ltd (ASX: CYT) announced today that it has filed an Investigational New Drug Application (IND) with the US Food and Drug Administration (FDA) for its novel, potent orally active JAK2 inhibitor CYT387. Following FDA review, the company int...

Onyx Pharmaceuticals Acquires Option to License Novel Highly Specific JAK2 Inhibitors From S*BIO

EMERYVILLE, Calif., Jan. 6 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced that it has acquired an option to license rights to SB1518, an orally available, potent, and selective inhibitor of Janus Kinase 2 (JAK2), and SB1578, also a JAK2 inhibitor, from S*BIO...

S*BIO Announces Collaboration with Onyx for JAK2 Inhibitors in the North American and European Markets

S*BIO Receives $25 Million Upfront Payment and Equity Investment and Eligible to Receive Additional $525 Million in Option & License Fees and Milestone Payments SINGAPORE, Jan. 6 /PRNewswire/ -- S*BIO Pte Ltd today announced that the company has entered into a Development Collaboration, a...

S*BIO's Oral JAK2 Inhibitor SB1518 Demonstrates Therapeutic Potential for the Treatment of Myeloproliferative and Other Hematological Disorders

Data Presented on Three S*BIO Compounds at The American Society of Hematology 2007 SINGAPORE, Dec. 10 /PRNewswire/ -- S*BIO Pte Ltd today announced the data presentation on its most advanced compounds at The American Society of Hematology 49th Annual Meeting and E...

New drug for children with high-risk leukemia

...he first researchers to discover a mutation of the jak2 protein in patients with Down syndrome, the Tel Av...e based on Dr. Izraeli's original discovery of the jak2 in Down syndrome, published recently in the presti...ccording to Dr. Izraeli, a similar mutation of the jak2 in Down syndrome and leukemia causes Polycythemia ...

SuperGen Reports 2008 Fourth Quarter and Year-End Financial Results

... clinically relevant concentrations. Abstract 571: Modulation of jak2 signaling pathways in vitro and in vivo by SGI-1252, a small molecule jak2 inhibitor. November 2008: The Company ann...

Experimental Drug Fights Bone Marrow Cancers

...as "very effective" against a specific type of cancer cell driven by an enzyme mutation called JAK2-V617F. The drug binds to the V617F mutation in the jak2 enzyme. "In the mouse model, the drug blocked JAK2-V617F, normalized blood counts and reduced enlarged spleens back to a normal size. It is a very ...

Late-breaking data to be presented at the American Society of Hematology Annual Meeting

...ous research has detected mutations in other genes jak2 and MPL in the blood stem cells of patients with myeloproliferative disorders. These jak2 and MPL defects cause the overproduction of mature...velopment in myeloproliferative disorders with the jak2 V617F mutation led researchers to identify two sub...

JCI online early table of contents: July 10, 2008

...quiescence by binding a signaling protein known as jak2 after it was activated following binding of the so... molecule Lnk, TPO-initiated signaling from Mpl to jak2 goes unchecked and the number of HSCs produced is ...al and quiescence through direct interactions with jak2 AUTHOR CONTACT: Wei Tong Children's Hospital ...

Stem cell research leads to potential new therapy for rare blood disorder

...AS, outlining the discovery that a mutation in the jak2 signaling pathway in patients with a type of MPD c...blood stem cells, engineered to contain the mutant jak2 gene, into mouse models with a suppressed immune s...del, achieving similar results. We found that the jak2 mutation was necessary and sufficient, by itself, ...

JAK2 in Medical Technology

TargeGen Announces Successful Completion of Patient Enrollment in Clinical Trial of JAK2 Inhibitor TG101348 in Myelofibrosis Patients and Scheduled Presentation of Preliminary Trial Data at EHA Conference in Berlin

SAN DIEGO, May 14 /PRNewswire/ -- TargeGen, Inc. today announced that the Company successfully completed enrollment of a multi-center clinical trial of TG101348, an oral, potent, and highly selective inhibitor of JAK2 in patients with myelofibrosis on May 7, 2009. (Logo: http://www.newscom....

Ipsogen Expands its US Market Presence Through Licensing Agreement With ARUP Laboratories for the Commercialization of JAK2 Molecular Diagnostic Assays

MARSEILLE, France, May 4 /PRNewswire-FirstCall/ -- Ipsogen SA (Alternext - FR0010626028 - ALIPS), a molecular diagnostic company specialized in the development, the manufacturing and the commercialization of diagnostic assays for breast cancer and leukemia, today announces the signature of an ...

TargeGen Affiliates Scheduled for Oral Presentation of Interim Clinical Trial Data at 2008 ASH Meeting in San Francisco for TG101348, a Potent, Selective, Oral JAK2 Inhibitor in Myeloproliferative Disease Patients

SAN DIEGO, Dec. 1 /PRNewswire/ -- TargeGen has announced that an oral presentation of preliminary results from a multi-center, US-based clinical trial of TG101348 in myeloproliferative disease patients has been scheduled at the 2008 American Society of Hematology (ASH) Meeting. Details o...

S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis

SINGAPORE, Dec. 1 /PRNewswire/ -- S*BIO Pte Ltd today announced the initiation of a Phase 1/2 clinical trial of SB1518, a potent and orally-active JAK2 inhibitor, in leading medical centers in Australia for patients with chronic idiopathic myelofibrosis (CIMF). The trial is designed to e...

Cytopia Scientific Presentations on JAK2 Inhibitor Program

MELBOURNE, Australia, Oct. 16 /PRNewswire/ -- Cytopia Limited (ASX: CYT) will present data on its JAK2 inhibitor program at two important scientific meetings this month. Dr Emmanuelle Fantino, Head of Biology at Cytopia, will present a lecture entitled Targeted JAK2 Inhibitors for Myeloproli...

S*BIO Initiates U.S. Phase I Clinical Trials of Oral JAK2 Inhibitor SB1518 for the Treatment of Hematological Malignancies

SINGAPORE, Sept. 18 /PRNewswire/ -- S*BIO Pte Ltd today announced the initiation of multi-center Phase I clinical trials of SB1518, a potent and orally-active JAK2 inhibitor, in patients with leukemia and certain types of lymphoma. These first Phase I trials for SB1518 comprise of ascending do...

Cytopia Appoints Study Chairman for JAK2 Clinical Trial

MELBOURNE, Australia, July 29 /PRNewswire-FirstCall/ -- Cytopia Limited (ASX: CYT) has appointed Dr. Ayalew Tefferi, Professor of Medicine and Hematology at the Mayo Clinic College of Medicine, as Clinical Study Chair for the company's Phase I/II study in patients with myelofibrosis. Dr. Tef...

SuperGen's JAK2 Inhibitor, SGI-1252, Inhibits in Vivo Tumor Cell Proliferation

DUBLIN, Calif., June 16 /PRNewswire-FirstCall/ -- SuperGen Inc. (Nasdaq: SUPG ), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, today announced at the 13th Congress of the European Hema...

Cytopia Nominates JAK2 Clinical Candidate for Myeloproliferative Disorders

Clinical study to commence late this year MELBOURNE, Australia, March 17 /PRNewswire/ -- Cytopia Limited (ASX: CYT) has selected CYT387, a selective and potent JAK2 inhibitor, for formal preclinical development to treat myeloproliferative disorders (MPDs). This follows extensive...

TargeGen Announces Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients

SAN DIEGO, Jan. 31 /PRNewswire/ -- TargeGen, Inc. today announced that the Company has started a multi-center Phase I/II clinical trial of TG101348, an oral, potent, and highly selective inhibitor of JAK2 in patients with myeloproliferative diseases. (Logo: http://www.newscom.com/cgi-bin/pr...

JAK2 in Biological News

Genetic abnormality may increase risk of blood disorders

...found that an inherited alteration in the gene for jak2 a protein with enzymatic activity that is linked ...isorders. Importantly, patients who inherited this jak2 alteration were predisposed to acquiring another jak2 mutation on the same DNA strand. According to the ...

Weill Cornell science briefs June/July 2008

...a way around splenectomy. After giving mice with Cooley's a compound called jak2 inhibitor, the researchers found that the mice's spleens shrunk to normal s...odysplastic syndromes -- another blood disorder) blocks the activity of the jak2 gene that is highly expressed in Cooley's anemia, and is believed to play a...

Avoiding Spleen Removal for Cooley's Anemia SufferersAvoiding spleen removal for Cooley's anemia suf

...a way around splenectomy. After giving mice with Cooley's a compound called jak2 inhibitor, the researchers found that the mice's spleens shrunk to normal s...odysplastic syndromes -- another blood disorder) blocks the activity of the jak2 gene that is highly expressed in Cooley's anemia, and is believed to play a...

Major link in brain-obesity puzzle found

...ody’s messenger boy to the brain for “stop eating, we’re full?messages, and jak2 helps receive those messages as they arrive, SH2B1’s partnership with jak2 is an important one. In a previous paper, Rui and his former mentor and cur...

Mutation in blood stem cells provides clues to cancer development

... The scientists discovered that a mutation in the jak2 signaling pathway allows the cells to bypass the b...an pinpoint an inhibitor that directly targets the jak2 mutant allele, we can fight the disease without in...istant to current therapies. The discovery of the jak2 mutation in stem cells in patients with PV is an i...

JAK2 in Biological Technology

Cytopia Scientific Presentation on JAK2 Inhibitor Program at American Chemical Society Conference

MELBOURNE, Australia, March 23 /PRNewswire/ -- Cytopia Limited (ASX: CYT) today announced that it will present data on its JAK2 program at the American Chemical Society Spring meeting, currently underway in Salt Lake City, Utah, USA. Dr Tracy Nero, Senior Scientist at Cytopia, will be presen...

Presentation on Cytopia's JAK2 Inhibitor Program in Myeloproliferative Disorders

MELBOURNE, Australia, Dec. 7 /PRNewswire/ -- Data on Cytopia's (ASX: CYT) JAK2 inhibitor CYT387 will be presented at the 50th American Society of Hematology conference in San Francisco. The talk will be presented by Dr Thomas Bumm of Oregon Health and Sciences University and will overview the st...

S*BIO Receives Orphan Drug Designation for JAK2 Inhibitor SB1518 for the Treatment of Myeloproliferative Disorders

SINGAPORE, May 13 /PRNewswire/ -- S*BIO Pte Ltd today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to SB1518, its potent and orally-active JAK2 inhibitor for the treatment of myeloproliferative disorders (MPD). The FDA accepted S*BIO's applicat...

Cytopia Presentation on JAK2 Inhibitor at American Association for Cancer Research

MELBOURNE, Australia, April 9, 2008 /PRNewswire/ -- Cytopia Limited (ASX: CYT) today announced that it is presenting data on its JAK2 inhibitor at the American Association for Cancer Research Annual Meeting being held in San Diego, California. The meeting involves approximately 17,000 particip...

Oral VDA CYT997 - Phase I Clinical Trial Presentation at ASCO

...trialed in Phase II clinical studies. Cytopia is continuing to build on its range of JAK inhibitors and kinase expertise, with CYT387, a novel oral jak2 inhibitor focused on the treatment of myeloproliferative disorders, expected to enter Phase I clinical studies in mid 2009. Website: www.cytopi...

Biomedical Sciences Companies Expanding in Asia Invested More Than US$500 Million in Singapore

... under two licensing agreements with Onyx and Tragara to develop oncology drugs. S*BIO's agreement with Onyx will include the development of SB1518, a jak2 inhibitor that received orphan drug designation from the U.S. Food and Drug Administration (FDA) in 2008. The Institute of Materials Research a...

Cytopia Presentation on VDA CYT997 at AACR Conference

...ng trialed in Phase II clinical studies. Cytopia is continuing to build on its range of JAK inhibitors and kinase expertise, with CYT387, a novel oral jak2 inhibitor focused on the treatment of myeloproliferative disorders, expected to enter Phase I clinical studies in 2009. Website: www.cytopia.com.a...

S*BIO Receives BioSpectrum Editor's Choice, Emerging BioScience Company of Singapore Award

...ress we made in moving our leading candidates, the jak2 inhibitors SB1518 and SB1578, the HDAC inhibitor S... in 2007. SB1518, S*BIO's potent and orally-active jak2 inhibitor, also entered the clinic in 2008 and has...velop and commercialize SB1518 and its other novel jak2 inhibitor, SB1578. S*BIO's SB1317, a novel multi-...

NeoGenomics Announces Fourth Quarter and Full Year 2008 Financial Results

...also pleased to report that in Q4 we began performing molecular genetic testing in-house. During Q4, we brought up and validated both the BCR/ABL and jak2 molecular tests and began to offer them to clients. Although molecular testing volumes are currently modest, by bringing this capability in-house, we...

Cytopia Letter to Progen Shareholders

...its range of JAK inhibitors and kinase expertise, with CYT387, a novel oral jak2 inhibitor focused on the treatment of myeloproliferative disorders, expecte...its range of JAK inhibitors and kinase expertise, with CYT387, a novel oral jak2 inhibitor focused on the treatment of myeloproliferative disorders, expecte...

JAK2 in Biological Products

Rabbit Anti-JAK2, phospho (Tyr1007) Polyclonal Antibody, Unconjugated from Abcam

Description:... Rabbit polyclonal to jak2 (phospho Y1007) ( Abpromise for all tested applications). Antigen: Synthesized phosphopeptide derived from human jak2 around the phosphorylation site of tyrosine 1007 (K-E-Y P -Y-K). Entrez ...
Company:Abcam